ArticleShock (Augusta, Ga.)2026
SIRT2 Regulates EX VIVO PBMC Adhesion in Septic Shock Patients.
Article in Shock (Augusta, Ga.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSeptic shock (SS) is deadly. Sepsis-immune response transitions from an endotoxin-sensitive, hyper-inflammatory phase to an endotoxin-tolerant hypo-inflammatory phase. In mice, we implicated sirtuin 2 (SIRT2) for prolonged hypo-inflammation using leukocyte adhesion, the earliest in vivo inflammatory response to cytokine, chemokine, and metabolite stimuli. The role of SIRT2 in human sepsis remains unknown. We hypothesized that (1) peripheral blood mononuclear cells (PBMCs) adhesion response can be used as a physiological biomarker of hypo-inflammation, and (2) SIRT2 regulates the functions of PBMCs and macrophages during the hypo-inflammatory phase of human sepsis.
methodsWe stimulated control and SS whole blood and PBMCs ± lipopolysaccharide (LPS) and investigated plasma cytokines, PBMC cell adhesion to intercellular adhesion molecule-1-coated plates, adhesion molecule CD18 activation, SIRT2 expression, and cytokine response. In adhesion-/endotoxin-tolerant PBMCs and THP-1 cells treated ± SIRT2 inhibitor AK-7, we analyzed cell adhesion, CD18 activation, and transmigration ± LPS. In monocyte-derived macrophages from SS versus controls ± AK-7, we analyzed phagocytosis.
resultsWe found the following: (1) Muted plasma tumor necrosis factor and interleukin-1β-response to LPS in SS versus control (endotoxin tolerance); (2) endotoxin-tolerant SS-PBMCs exhibit high SIRT2 expression, and muted adhesion (adhesion tolerance), CD18 activation, and transmigration with LPS; and (3) SIRT2 inhibitor AK-7 reverses endotoxin and adhesion tolerance in SS-PBMCs via CD18 activation, reverses the defective transmigration of endotoxin-tolerant PBMCs, and improves phagocytosis in monocyte-derived macrophages from SS patients.
conclusionsPBMC adhesion, a physiological biomarker, can be used to detect hypoinflammation. Defective PBMC and macrophage function in SS patients occur via high SIRT2 expression. SIRT2 inhibition is a potential therapeutic strategy for treating sepsis-associated hypo-inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.